Phase 4 N=142 A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.
Renal Cell Carcinoma
Primary: PFS (Progression-Free Survival) — 27.71 Weeks
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=134 Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Primary: Progression-free Survival (PFS) - All Participants — 7.4 months
N/A N=102 Observational Study Evaluating The Efficacy And Effects On Quality Of Life Of Targeted Treatments Following TKIs In mRCC
Renal Cell Carcinoma
Primary: Progression Free Survival (PFS) — NA months
Phase 2 N=25 SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients
Kidney Cancer Metastatic · Kidney Cancer · Kidney Cancer, Stage IV
Primary: Number of Participants With Treatment-related Adverse Events Grade 3 or Higher as Assessed by CTCAE v4.0 — 9 Participants
N/A N=19 Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
Kidney Cancer · Renal Cell Carcinoma · Metastatic Renal Cell Carcinoma
Primary: Initial Objective Response- First Participation — 5; 1; 7; 4 Participants
N/A N=1,349 Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan
Renal Cell Carcinoma
Primary: Duration of Sunitinib and Pazopanib Treatment in Participants — 171; 114.5 days
Phase 2 N=55 Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Overall Response Rate — 27 percentage of patients
Phase 2 N=108 Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
Advanced Non-clear Cell Renal Cell Carcinoma
Primary: Anti-tumor Activity as Measured by Median Progression Free Survival Time — 5.6; 8.3 Months — p=0.157
Phase 2 N=64 Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)
Carcinoma, Renal Cell
Primary: Objective Response Rate (Percentage of Participants With Complete Response [CR] or Partial Response [PR]): Independent Review Committee Assessment — 50.0 percentage of…
Phase 4 N=29 Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib
Metastatic Renal Cell Carcinoma (mRCC)
Primary: Percentage of Progression-free Patients by Month 6 — 8.3; 46.2 Percentage of participants
Phase 1 N=25 Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response
Renal Cell Cancer
Primary: Metabolic Response — 5 participants
Phase 3 N=435 Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma
Carcinoma, Renal Cell
Primary: Progression-free Survival — 9.2; 4.2 months — p=.0000001
Phase 2 N=50 Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma
Renal Cell Carcinoma · Kidney Cancer
Primary: Progression Free Survival (PFS) — 11 months
Phase 2 N=10 Carfilzomib in Refractory Renal Cell Carcinoma (RCC)
Kidney Cancer
Primary: Progression Free Survival (PFS) of Carfilzomib Therapy in Participants With Refractory Or Intolerant to Prior Therapy — 1.8 Months
Phase 2 N=39 A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Primary: Percentage of Participants With Objective Response (Objective Response Rate) — 5.1 percentage of participants
Phase 2 N=25 Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Progression-free Survival — 12 Weeks
Phase 3 N=39 Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)
Carcinoma, Renal Cell
Primary: Pharmacokinetics Measured as Area Under Curve (AUC[0-12h]) — 35.5; 5.7 mg*hour/Liter
Phase 2 N=39 Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Best Overall Response Rate — 5 percentage of participants
Phase 2 N=41 Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Renal Cell Carcinoma · Kidney Cancer
Primary: 4-month Progression-Free Survival Rate — 65 percentage of participants — p=0.081
Phase 2 N=30 Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours
Renal Cell Carcinoma
Primary: Toxicities Measured Using CTCAE Version 4.03 — 4 participants with G3 TRAEs
Phase 2 N=106 A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
Carcinoma, Renal Cell
Primary: Number of Subjects With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST) — 35 participants
Phase 2 N=92 Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma
Renal Cell Carcinoma
Primary: Best Response by RECIST v1.0 — 0; 1; 0; 1 Participants
N/A N=102 Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments
Metastatic Renal Cell Carcinoma (mRCC)
Primary: Overall Survival (OS) After Initiation of Second Line Sunitinib Therapy — 15.6 Months
Phase 2 N=127 Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors
Locally Advanced or Metastatic Renal Cell Carcinoma
Primary: Cohort A: Objective Response Rate (ORR) Assessed by Independent Central Review — 40.5 percentage of participants
Phase 2 N=57 Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)
Renal Cell Carcinoma
Primary: To Evaluate the Efficacy of Combining Everolimus and Bevacizumab in Patients With Advanced RCC of Non-clear Cell Histology — 78 percent of participants
Phase 2 N=168 BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
Renal Cell Carcinoma
Primary: Progression Free Survival (PFS) — 2.63; 4.11; 4.17 Months
N/A N=1,769 Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib
Metastatic Renal Cell Carcinoma
Primary: Overall Survival — 52.1; 31.5; 9.8 months
Phase 2 N=52 Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma
Kidney Neoplasms
Primary: Percentage of Participants With Objective Response (OR) — 44.2 Percentage of participants
Phase 2 N=96 MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma
Clear-cell Metastatic Renal Cell Carcinoma
Primary: Progression-Free Survival (PFS) — 3.8; 3.6; 3.1 months — p==0.388
Phase 2 N=19 Phase II Study of Alternating Sunitinib and Temsirolimus
Metastatic Renal Cell Carcinoma
Primary: Progression Free Survival — 8.8 Months